PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT04022785 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myelodysplastic/Myeloproliferative Neoplasm
Myeloproliferative Neoplasm

Interventions

DRUG: Azacitidine
DRUG: BRD4 Inhibitor PLX51107

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]